Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Zehbe, Ingeborg ^a   Lichtig, Hava ^b   Westerback, Ashley ^a   Lambert, Paul F ^c   Tommasino, Massimo ^d   Sherman, Levana ^b  

^a Thunder Bay Regional Research Institute   (Canada)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA CATENIN; CYTOKERATIN 10; CYTOKERATIN 14; CYTOKERATIN 5; DACTINOMYCIN; GLUTAMINE; GLYCINE; LEUCINE; PROTEIN E6; PROTEIN P53; T CELL FACTOR PROTEIN; TYROSINE; VALINE; WNT PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; MUTANT PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN;

AMINO ACID SUBSTITUTION; ANOIKIS; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CELL CULTURE; CELL CYCLE ARREST; CELL IMMORTALIZATION; CONTROLLED STUDY; CULTURE MEDIUM; EUROPE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HYPERPLASIA; IMMUNOASSAY; KERATINOCYTE; LIPID RAFT; PHENOTYPE; SEROPREVALENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUSPENSION; UTERINE CERVIX CANCER; VIROGENESIS; VIRUS DETECTION; CARCINOMA; CELL STRAIN HEK293; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; PAPILLOMAVIRUS INFECTION; PHYSIOLOGY; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS CELL TRANSFORMATION;

HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

CARCINOMA; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HEK293 CELLS; HUMANS; MUTANT PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 79959481486     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-77     Document Type: Article

References (52)

1. Zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996, 1288:55-78.
2. DiMaio D, Liao JB. Human papillomaviruses and cervical cancer. Adv Virus Res 2006, 66:125-140.
3. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecologic Oncology 2008, 110:S4-S7. 10.1016/j.ygyno.2008.07.045, 18760711.
4. Lizano M, Berumen J, Garcia-Carranca A. HPV-related carcinogenesis: Basic concepts, viral types and variants. Arch Med Res 2009, 40:428-434. 10.1016/j.arcmed.2009.06.001, 19853182.
5. Bernard HU, Calleja-Macias IE, Dunn ST. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer 2006, 118(5):1071-1076. 10.1002/ijc.21655, 16331617.
6. Tidy JA, Vousden KH, Farrell PJ. Relation between infection with a subtype of HPV16 and cervical neoplasia. Lancet 1989, 1(8649):1225-1227. 10.1016/S0140-6736(89)92329-5, 2566780.
7. Zehbe I, Wilander E, Delius H, Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 1998, 58:829-833.
8. Zehbe I, Voglino G, Delius H, Wilander E, Tommasino M. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 1998, 352:1441-1442. 10.1016/S0140-6736(05)61263-9, 9807995.
9. Xi LF, Demers GW, Koutsky LA, Kiviat NB, Kuypers J, Watts DH, Holmes KK, Galloway DA. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis 1995, 172:747-755. 10.1093/infdis/172.3.747, 7658068.
10. Xi LF, Koutsky LA, Hildesheim A, Galloway DA, Wheeler CM, Winer RL. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev 2007, 16:4-10. 10.1158/1055-9965.EPI-06-0670, 17220325.
11. Zehbe I, Voglino G, Wilander E, Delius H, Edler L, Klimek F, Andersson S, Tommasino M. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 2001, 61:608-611.
12. Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H, Gissmann L, Wilander E, Tommasino M. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer 2001, 94:711-716. 10.1002/ijc.1520, 11745467.
13. Berumen J, Ordonez RM, Lazcanao E, Salmeron E, Galvan SC, Estrada RA, Yunes E, Garcia-Carranca A, Gonzalez-Lira G, Madrigal-de-la-Campa A. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 2001, 93:1325-1330. 10.1093/jnci/93.17.1325, 11535707.
14. Kämmer C, Tommasino M, Syrjanen S, Delius H, Hebling U, Warthorst U, Pfister H, Zehbe I. Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease. Br J Cancer 2002, 86:269-273. 10.1038/sj.bjc.6600024, 2375181, 11870518.
15. Xi LF, Koutski LA, Hildesheim A, Galloway DA, Wheeler CM, Winer RI. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev 2007, 16:4-10. 10.1158/1055-9965.EPI-06-0670, 17220325.
16. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996, 69:364-368. 10.1002/(SICI)1097-0215(19961021)69:5<364::AID-IJC2>3.0.CO;2-3, 8900368.
17. Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 2002, 3:11-16. 10.1016/S1470-2045(01)00617-9, 11905599.
18. Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, Koutski LA. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst 2006, 98:1045-1052. 10.1093/jnci/djj297, 16882941.
19. Grodzki M, Besson G, Clavel C, Franceschi S, Arslan A, Birembaut P, Tommasino M, Zehbe I. Increased risk for cervical disease progression of French women infected with the human papillomavirus 16 E6-350G variant. Cancer Epidemiol Biomarker Prev 2006, 15:820-822.
20. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, Villa LL. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007, 120:1763-1768. 10.1002/ijc.22481, 17230525.
21. Lee K, Magalhaes I, Clavel C, Birembaut P, Tommasino M, Zehbe I. Distribution of human papillomavirus 16 E6, L1, L2 and E2 gene variants in pre-malignant cervical disease. Virus Res 2008, 131:106-110. 10.1016/j.virusres.2007.08.003, 17869365.
22. Conrad-Stoppler M, Ching K, Stoppler H, Clancy K, Schlegel R, Icenogle J. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 1996, 70(10):6987-6993. 190749, 8794343.
23. Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, Krishna S. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol 2004, 78:5934-5945. 10.1128/JVI.78.11.5934-5945.2004, 415794, 15140991.
24. Lichtig H, Algrisi M, Botzer LE, Abadi T, Verbitzky Y, Jackman A, Tommasino M, Zehbe I, Sherman L. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 2006, 350:216-227. 10.1016/j.virol.2006.01.038, 16519914.
25. Asadurian Y, Kurilin H, Lichtig H, Jackman A, Gonen P, Tommasino M, Zehbe I, Sherman L. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes. J Med Virol 2007, 79:1751-1760. 10.1002/jmv.20978, 17854024.
26. Zehbe I, Richard C, DeCarlo CA, Shai A, Lambert PF, Lichtig H, Tommasino M, Sherman L. Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis. Virology 2009, 383:69-77. 10.1016/j.virol.2008.09.036, 2945146, 18986660.
27. Richard C, Lanner C, Naryzhny SN, Sherman L, Lee H, Lambert PF, Zehbe I. The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalence in cervical cancer. Oncogene 2010, 29:3435-3445. 10.1038/onc.2010.93, 20383192.
28. Golan M, Hizi A, Resau JH, Yaal-Hohoshen N, Reichman H, Keydar I, Tsarfaty I. Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker. Neoplasia 2008, 10:521-533. 2386537, 18516289.
29. Lichtig H, Gilboa A, Jackman A, Gonen P, Levav-Cohen Y, Haupt Y, Sherman L. HPV16 E6 augments Wnt signaling in an E6AP-dependent manner. Virology 2010, 396:47-58. 10.1016/j.virol.2009.10.011, 19896689.
30. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Hedrick L, Cho KR. Human papillomavirus 16 E6 expression disrupts the 53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993, 90:3988-3992. 10.1073/pnas.90.9.3988, 46431, 8387205.
31. Foster SA, Demers GW, Etscheid BG, Galloway DA. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virology 1994, 68:5698-5705. 236972, 8057451.
32. Mack JA, Anand S, Maytin EV. Proliferation and cornification during development of the mammalian epidermis. Birth Defects Research (Part C) 2005, 75:314-329.
33. Koster MI, Roop DR. Mechanisms regulating epithelial stratification. Ann Rev Cell Dev Biol 2007, 23:93-113.
34. Allen-Hoffmann BL, Schlosser SJ, Ivarie CA, Sattler CA, Meisner LF, O'Connor SL. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J Invest Dermatol 2000, 114:444-455. 10.1046/j.1523-1747.2000.00869.x, 10692102.
35. Hansen LA, Woodson RL, Holbu S, Strain K, Lo YC, Yuspa SH. The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. Cancer Res 2000, 60:3328-3332.
36. Huitfeldt HS, Heyden A, Clausen OP, Thrane EV, Roop D, Yuspa SH. Altered regulation of growth and expression of differentiation-associated keratins in benign mouse skin tumors. Carcinogenesis 1991, 12:2063-2067. 10.1093/carcin/12.11.2063, 1718620.
37. Marconi A, Atzei P, Panza C, Fila C, Tiberio R, Truzzi F, Wachter T, Leverkus M, Pincelli C. FLICE/caspase-8 activation triggers anoikis induced by beta1-integrin blockade in human keratinocytes. J Cell Sci 2004, 117:815-823. 10.1242/jcs.01080, 14963022.
38. Uren A, Fallen S, Yuan H, Usubutun A, Kucukali T, Schlegel R, Toretsky JA. Activation of the canonical Wnt pathway during genital keratinocyte transformation: A model for cervical cancer progression. Cancer Res 2005, 65:6199-6206. 10.1158/0008-5472.CAN-05-0455, 16024621.
39. Perez-Pereira C, Vazquez-Ortiz G, Lopez-Romero R, Pina-Sanchez P, Moreno J, Salcedo M. Genome wide expression analysis in HPV cervical cancer: identification of altered metabolic pathways. Infect Agent Cancer 2007, 2:16-26. 10.1186/1750-9378-2-16, 2034543, 17822553.
40. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 2009, 384:324-334. 10.1016/j.virol.2008.11.017, 2674106, 19081593.
41. Blanton RA, Perez-Reyes N, Merrick DT, McDougall JK. Epithelial cells immortalized by human papillomaviruses have premalignant characteristics in organotypic culture. Am J Pathol 1991, 138:673-85. 1886282, 1848042.
42. McCance DJ, Kopan R, Fuchs E, Laimins LA. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci USA 1989, 85:7169-7173.
43. Ruiz S, Santos M, Segrelles C, Leis H, Jorcano JL, Berns A, Paramio JM, Vooijs M. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 2004, 131:2737-2748. 10.1242/dev.01148, 15148303.
44. Drozdoff V, Pledger WJ. Commitment to differentiation and expression of early differentiation markers in murine keratinocytes in vitro are regulated independently of extracellular calcium concentrations. J Cell Biol 1993, 123:909-919. 10.1083/jcb.123.4.909, 2200160, 7693721.
45. Moody CA, Fradet-Turcotte A, Archambault J, Laimins LA. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc Natl Acad Sci USA 2007, 104:19541-19546. 10.1073/pnas.0707947104, 2148325, 18048335.
46. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 2003, 94:225-229. 10.1111/j.1349-7006.2003.tb01424.x, 12824913.
47. Clevers H. Wnt/β-catenin signalling in development and disease. Cell 2006, 127:469-480. 10.1016/j.cell.2006.10.018, 17081971.
48. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, Huelsken J. Cutaneous cancer stem cell maintenance is dependent on β-catenin signaling. Nature 2008, 452:650-653. 10.1038/nature06835, 18385740.
49. Lagunas-Martinez A, Madrid-Marina V, Gariglio P. Modulation of apoptosis by early human papillomavirus proteins in cervical cancer. Biochim Biophys Acta 2010, 1805:6-16.
50. Park J, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, McLaughlin M, Veenstra TD, Nusse R, McCrea PD, Artandi SE. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009, 460:66-72. 10.1038/nature08137, 19571879.
51. Bontkes HJ, van Duin M, De Gruijil TD, Duggan-Keen MF, Walboomers JM, Stukart MJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ, Stevens FR, Dyer PA, et al. HPV 16 infection and progression of cervical intraepithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer 1998, 78:166-171. 10.1002/(SICI)1097-0215(19981005)78:2<166::AID-IJC8>3.0.CO;2-X, 9754647.
52. Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Joung LS, Stern PL. The association of an HPV 16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med 1995, 1:464-470. 10.1038/nm0595-464, 7585096.